{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 37,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "Clinical trial data presentation for oncology drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/20",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.73,
        "x": 0.04,
        "y": 0.84
      },
      "kind": "disclaimer",
      "text": "Low-grade constipation observed is consistent with baseline levels seen in advanced cancer patients. Interim data- Data cut-off of June 2, 2022. Note: CTCAE definitions.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51df73b5-4ce4-45d6-bf6f-77c375511e14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.36,
        "x": 0.61,
        "y": 0.23
      },
      "kind": "list",
      "text": "No treatment-related deaths; Few treatment-related SAEs; No AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2204a676-8315-41f4-b548-87ea6d530d0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.63,
        "w": 0.55,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "table",
      "text": "Adverse events table comparing BA3011 and BA3011 + Opdivo",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ef87d4a-7ceb-4f1c-8e99-0dd5437e3b22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.34,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a85bb0-2ae4-4ef0-a3ae-f10a400a1319",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Promising safety and tolerability profile emerging in NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faf264b3-9cab-4d47-912f-1d2aa4f05a14",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "f679baef-3533-4013-8d35-84ea48c6741f",
      "evidence": "table/data: Adverse events table comparing BA3011 and BA3011 + Opdivo",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 10,
      "beatId": "c5004055-d5ec-4e67-8d3c-a6006b26dc07",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating traction.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 27,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70b35119-d82b-4aab-a655-ee1318f5401a",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating potential for quick wins and big bets.",
      "position": 2,
      "objective": "What are the potential quick wins and big bets for BioAtla's CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}